

U.S. Department of COMMERCE
United States Patent and Trademark Office

HARR0032-101
(DG/P21306US3)

2. Name and address of receiving party(ies):

Name: M.L. Laboratories PLC

Street Address: 17 Hanover Square, 5th Floor

City: **London W1S 1HU**

Country: England

Additional Name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment ☐ Merger

☐ Security Agreement ☐ License Agreement

☐ Change of Name ☐ Other

☐ **Government Interest Assignment**

☐ Executive Order 9424, Confirmatory License

Additional name of conveying party(ies) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s):

B. Patent No.(s):

10/607,479; Filing Date: 06/26/2003

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning this document should be mailed:

6. Total number of applications and patents involved: One

Name: **Doreen Yatko Trujillo**
COZEN O'CONNOR, P.C.
1900 Market Street, 6th Floor
Philadelphia, Pennsylvania 19103-3508
215.665.5593 – Direct Line
215.701.2005 – Direct Facsimile
dttrujillo@cozen.com – Email Address

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00

☐ Authorized to be charged by credit card

☒ Authorized to be charged to deposit account
number 50-1275

☐ Enclosed

☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number 50-1275

Authorized User Name, Doreen Yatko Trujillo, Reg. 35,719

9. Signature;

Doreen Yatko Trujillo/Reg. No. 35,719

Name of Person Signing/ Reg. No.

Signature _____

Date _____

Total number of pages including cover sheet, attachments, and documents: Seven

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:


Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
P.O. Box 1480
Alexandria, VA 22313-1480

PATENT

REEL: 015589 FRAME: 0457

700145402

CH \$40.00 501275 10607479



STRINGER SAUL

DATED 13 June 2002


(1) COBRA THERAPEUTICS LIMITED

and

(2) M.L. LABORATORIES PLC

ASSIGNMENT

17 Hanover Square London W1S 1HU
Tel: 020 7917 8500 Fax: 020 7917 8555

STRINGER SAUL

THIS AGREEMENT is made on

13 June

2002

BETWEEN

- (1) COBRA THERAPEUTICS LIMITED, (registered no 271054) whose registered office is at The Science Park, University of Keele, Keele, Newcastle, Staffordshire ST5 5SP ("Assignor").
- (2) M.L.LABORATORIES PLC (registered no 2148607) whose registered office is at 5TH Floor, 17 Hanover Square, London W1S 1HU ("Assignee").

Recitals

- (A) By Sale Agreement of even date ("Hive Out Agreement") the Assignor sold and the Assignee purchased various assets including Patents as hereinafter defined.

Operative Provisions**1 Definitions**

In this agreement, the following words and expressions shall have the following meanings:

"Know-How"

the body of technical knowledge, technical experience and skills and all technical information, know-how, trade secrets, data, knowledge, advice and marketing experience (whether written or oral, including: reports, letters, designs (including any design registrations or applications therefor), drawings, formulae, processes, blueprints, training and operation manuals, specifications, materials, photographs and the like) relating in any manner whatsoever to the Patents and includes both the whole body of such knowledge, experience, skills and information and also any one or more parts of the

same;

"the Patents" the patents or patent applications set out in the Schedule ;

"the Technical Documentation" all manuals and other documentation in which the Know-How is recorded and all other technical and organisational documentation associated with the Know-How;

2 Assignment

- 2.1 In consideration of the parties entering into the Hive Out Agreement, Assignor hereby assigns all its rights, title and interest in the Patents and Know-How to Assignee free from encumbrances.

3 Assignor's obligations

3.1 Assignor agrees with Assignee

3.1.1 Registration of new proprietorship

- 3.1.1.1 at the request and expense of Assignee to execute any further document that Assignee may reasonably require to enable Assignee to formalise and become registered in any relevant patent registry as proprietor of the Patents;

3.1.2 Supply of Information

- 3.1.2.1 to inform Assignee of all technical information in its possession or control concerning the Know How and Patents; and

- 3.1.2.2 to supply Assignee with any Technical Documentation in its possession or control.

4 Governing law and disputes

This Agreement shall be governed by and construed in accordance with the law of England and the parties hereby submit to the exclusive jurisdiction of the English courts.

SCHEDULE

CTL Code	Number	Description	Status
1. Gene Delivery Technology			
1.1 Non-viral DNA delivery			
P0007/EP	EP 0 831922	Multipurp delivery EP	Pending substantive Examination
P0007/US/CIP2	09/007,692	Multipurp delivery US	Response to Final OA and CPA filed
P0007/ZA	96/4925	Multipurp delivery RSA	Granted
P0030/US	6218112B1	BIAcore US	Granted
P0035/US	09/023,406	CL22 US	Response to OA filed
P0035/EP	98904264.3	CL22 EP	Pending substantive Examination
P0035/AU	62211/98	CL22 AU	OA received
P0035/JP	10-535464	CL22 JP	Pending
P0046/AU	45848/00	Mellitin peptides (CP36)	Pending
P0046/CA	2370284	Mellitin peptides (CP36)	Pending
P0046/CN	00806815.1	Mellitin peptides (CP36)	Pending
P0046/EP	EP 1 173474	Mellitin peptides (CP36)	Pending
P0046/IL	145885	Mellitin peptides (CP36)	Pending
P0046/IN	IN/PCT/2001/00965DEL	Mellitin peptides (CP36)	Pending
P0046/JP	2000-614278	Mellitin peptides (CP36)	Pending
P0046/KP	2001-7013492	Mellitin peptides (CP36)	Pending
P0046/KR	PCT/GB00/01588	Mellitin peptides (CP36)	Pending
P0046/RU	2001132086	Mellitin peptides (CP36)	Pending
P0046/HK	EP 1 173474	Mellitin peptides (CP36)	Pending
P0046/US	09/558,791	Mellitin peptides (CP36)	OA received
2.2 DNA Vaccination			
P0020/EP	97903448.5	APC Europe	Response to OA filed 20:10:01
P0020/US/CIP3	09/221,050	APC US	Pending
P0020/AU	724716	APC Australia	Granted
P0020/CA	2244110	APC Canada	Pending
P0020/JP	9-528316	APC Japan	Pending
2.3 Targetting & transvection			
P0006/US	5,766,902	Electroporation	Granted
P0008/US	5,830,852	Insulin delivery US	Granted
P0008/AU	705060	Insulin delivery AU	Granted
3. Cancer Gene Therapy			
P0047/US	09/889,761	Phage selection US	awaiting voluntary publication
P0047/EP	EP1147218	Phage selection EP	awaiting Examination
P0047/CA	2,358,944	Phage selection	Examination not yet requested
P0063/GB1	0120294.4	Improved NTR	Priority year ends 21:08:02

P0063/GB2	0121662.1	Improved NTR	Priority year ends 21:08:02
P0063/US	60/326,846	Improved NTR	Priority year ends 21:08:02
P0038/EP	97928374.4	Quercetin prodrug EP	Pending
P0038/US	6,258,840B1	Quercetin prodrug US	Granted
P0038/AU	32694/97	Quercetin prodrug AU	Granted
P0038/CA	2258725	Quercetin prodrug CA	Pending
P0038/JP	10-502560	Quercetin prodrug JP	Pending
P0055/WO	WO 01/64739	TCF-resp element	Published with SR
P0055/US	09/798,128	TCF-resp element	Awaiting Examination


4.UCOE Technology

P0042/AU	50534/99	UCOE	Pending substantive examination
P0042/CA	2,333,852	UCOE	Pending
P0042/CN	1334878T	UCOE	Pending
P0042/EP	99954910.3	UCOE	Pending
P0042/HK	01104768.1	UCOE	Pending
P0042/JP	2000-561336	UCOE	Pending
P0042/KR	2001-7000883	UCOE	Pending
P0042/MX	PA/a/2001/000830	UCOE	Pending
P0042/US/C	09/358082	UCOE US/Cont	CPA filed 18:11:01
P0061/WO	PCT/GB01/04210	Artificial UCOE	PCT filed (20:09:01)
P0061/US	09/957,974	Artificial UCOE	Pending
		Flanking Selectable Element	
P0064/WO	PCT/GB02/01479	Flanking Selectable Element	Pending
P0064/US3	10/117,960	Flanking Selectable Element	Pending

Page 6

AS WITNESS the hands of the parties or their duly authorised representatives the day and the year first
above written

Signed by



for and on behalf of

COBRA THERAPEUTICS LIMITED

Signed by



for on and behalf of

M.L. LABORATORIES PLC